Tag:

Humira

Latest Headlines

Latest Headlines

AbbVie nabs FDA's orphan drug tag for Humira in HS

AbbVie is working to lessen its reliance on blockbuster Humira, which is already facing biosimilar competition in India. But it's also working to broaden the drug's label, and on that front, it got a boost from the FDA on Friday.

AbbVie says disappointing Viekira sales numbers are misleading

AbbVie's Humira is riding high, as usual--but according to the company's execs, in the U.S., it's riding higher than ever. The company's going to need to apply that market-share magic to new launch Viekira Pak, which fell short of analysts' Q1 sales estimates. But that effort is already going better than investors may think, management says.

Stellar Humira sales underscore AbbVie's need for replacement meds

AbbVie's working toward solutions to protect its top line against Humira's inevitable decline. For now, though, its workhorse is still getting the job done, and it delivered yet another double-digit leap in Q1 to help the company beat expectations.

Could a restructuring help protect AbbVie when revenue troubles hit?

It's no secret that AbbVie's sales are in for a shock once generic competition starts eating away at behemoth Humira. But worry not, investors: The company will be able to shield its EPS from the hit when the time comes, one analyst believes.  

Humira biosimilars will gut AbbVie's sales in 3 years, analyst says

Pharma analysts have different opinions on how much branded drugmakers will feel the heat from biosimilars--and when they'll feel it. But according to one Citi analyst, they're all underestimating the impact on AbbVie's top dog.

Amgen clears PhIII hurdle in crowded biosimilar race to topple Humira

Amgen wrapped up a second successful Phase III study of its Humira knockoff, ABP501, flagging its head-to-head success in a brief thumb's up announcing that the biosimilar hit its primary and key secondary endpoints. And barring any nasty surprises the positive readout on rheumatoid arthritis should give Amgen the ammunition needed to gun for an approval in a crowded field of late-stage contenders.

AbbVie rides high on Humira sales in Q4 but looks to new products for success in 2015

AbbVie posted promising fourth-quarter earnings fueled by the strong performance of blockbuster Humira. But the company is looking beyond its top-selling med in 2015, focusing on the development of new products to bolster its bottom line as it counters generic competition to some of its key moneymakers.

AbbVie needs more than its hep C nod to backfill Humira's looming patent loss

With Friday's approval of all-oral hep C regimen Viekira Pak, AbbVie's got a future blockbuster on its hands. And it couldn't have arrived soon enough.

AbbVie's Humira competition begins with Cadila's biosimilar launch in India

Indian drugmaker Zydus Cadila has launched a biosimilar of Humira in its home market--the first in a long line of in-development copies to threaten AbbVie's powerhouse med.

Which old meds hold their own with fast-growing Sovaldi, Tecfidera, and Xarelto? Try Humira and Revlimid

According to FirstWord Pharma, over the past four quarters, the 50 biggest-growing drugs delivered an absolute sales increase of $31 billion to their makers. While the top 5 slots on FWP 's list are filled with a who's who of recent, high-powered launches, AbbVie stalwart Humira is right up there with the new rollouts--and the list holds a few surprises lower down, too.